Has Harold Miller, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,133,521 in general payments to Harold Miller, MD across 1,799 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Harold Miller, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Harold Miller, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Harold Miller, MD

Endocrinology, Diabetes & Metabolism · Hammond, LANPI 1295707669

Payments from drug & device makers

$1,133,521in general payments, 2019–2025

Across 1,799 payments — averaging $630.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eli Lilly$248K
Novartis$201K
Corcept Therapeutics$147K
Bayer$115K
AbbVie$112K
Genentech, Inc.$84K
plus $227K from 54 others

$18,364in research payments, 2019–2025

Across 40 payments — averaging $459.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$11K
Corcept Therapeutics$7K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eli Lilly	40	$247,710
Novartis	17	$200,532
Corcept Therapeutics	176	$146,859
Bayer	82	$115,444
AbbVie	84	$111,759
Genentech, Inc.	18	$84,342
Recordati_rare_diseases_inc.	30	$67,181
F. Hoffmann-la Roche AG	14	$64,582
Pfizer	13	$30,345
Abbott	138	$26,794
Merck	74	$9,991
Mannkind Corporation	49	$4,948
Medtronic(2 entities)	124	$4,388
Insulet Corporation	25	$2,196
Lilly USA, LLC	121	$2,143
Novo Nordisk	100	$1,616
Amgen(2 entities)	65	$1,535
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	111	$1,494
Xeris Pharmaceuticals, Inc.	89	$1,378
Dexcom, Inc.	69	$1,336
AstraZeneca(2 entities)	47	$991
Sanofi-aventis U.S. LLC	66	$978
BETA Bionics, Inc.	17	$407
Amneal Pharmaceuticals LLC	27	$392
Antares Pharma, Inc.	14	$311
Boehringer Ingelheim	18	$299
Amarin Pharma, Inc.	15	$268
Zealand Pharma US, Inc.	9	$259
Lifescan, Inc.	13	$238
Ascendis Pharma Endocrinology Inc	7	$218
Radius Health, Inc.	10	$217
Senseonics, Incorporated	4	$186
BD	8	$175
Johnson & Johnson	12	$146
Valeritas, Inc.	4	$145
Currax Pharmaceuticals LLC	9	$139
IBSA Pharma Inc.	7	$119
Ascensia Diabetes Care US Inc.	5	$104
Cequr Corporation	2	$103
Embecta Corp.	5	$95
Nevro Corp.	5	$83
Madrigal Pharmaceuticals	3	$82
Alfasigma USA, Inc.	5	$77
Almatica Pharma LLC	3	$75
Esperion Therapeutics, Inc.	4	$72
Neurocrine Biosciences, Inc.	3	$66
Sequel Med Tech, LLC	4	$64
Idorsia Pharmaceuticals US Inc	4	$62
Shire North American Group Inc	3	$55
Halozyme Inc	3	$54
Clarus Therapeutics Inc.	3	$54
Acerus Pharmaceuticals Corporation	3	$52
Tolmar, Inc.	2	$44
Ultragenyx Pharmaceutical Inc.	2	$39
GRT US Holding, Inc.	2	$38
Regeneron Healthcare Solutions, Inc.	1	$34
Intra-sana Laboratories	1	$29
Tandem Diabetes Care, Inc.	1	$27
Rhythm Pharmaceuticals, Inc.	1	$25
Eisai Inc.	1	$19

How this compares

$1,133,521 in reported general payments places this provider in the 95th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.

See all endocrinology, diabetes & metabolism providers in Louisiana →

Medicare billing

Part B allowed, 2024

$126,435

Medicare patients

536

Services billed

1,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Hammond

Abdul KhanHammond$587K
Corey MajorsHammond$45K
Tuan Huy TranMetairie$2M
Timothy GilbertBaton Rouge$985K
Justin FontenotLafayette$905K
Vivian FonsecaNew Orleans$700K
Frank GreenwayBaton Rouge$669K
Ileana TandronSlidell$527K
Jonathan WiseMetairie$463K
Marideli ScanlanMarrero$446K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →